Displaying drugs 2501 - 2525 of 3304 in total
BTA9881
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
Matched Description: … BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota …
Dehydroascorbic acid
Dehydroascorbic acid is made from the oxidation of ascorbic acid. This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. In the body,...
Experimental
ENMD-1198
Investigational
PF-06650833
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … 06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified …
Recombinant Super-Compound Interferon
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
IDM-4
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling …
Merimepodib
Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
Investigational
HCV-086
HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.
Investigational
Matched Description: … small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus …
BBV152
BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel....
Investigational
Matched Description: … candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain ... Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations …
Capric acid
Decanoic acid is a solid. This compound belongs to the straight chain fatty acids. These are fatty acids with a straight aliphatic chain. The proteins that decanoic acid targets include furin, octanoyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase 1, peptostreptococcal albumin-binding protein, and putative uncharacterized protein tcp14.
Experimental
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Description: … [A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. ... [A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and ... [A193026] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased …
7,8-Diamino-Nonanoic Acid
Experimental
Technetium Tc-99m arcitumomab
Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
Experimental
Matched Description: … the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen …
EP0057
EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.
Investigational
Presatovir
Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Infections, and Respiratory Syncytial Virus (RSV) Infections.
Investigational
Matched Description: … (RSV), Respiratory Syncytial Virus Infections, and Respiratory Syncytial Virus (RSV) Infections. ... Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus …
Hemoximer
Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.
Investigational
Matched Description: … Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering …
CDX-6512
CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]
Investigational
Matched Description: … CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. …
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Matched Description: … PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor …
TT 173
TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental procedures.
Investigational
Matched Description: … TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such …
VPM4001
VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
Investigational
Matched Description: … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete …
SCIB1
SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
Investigational
Matched Description: … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate …
Sapablursen
Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid
Investigational
Matched Description: … Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary …
Odronextamab
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
Matched Description: … CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin ... A phase I clinical study (NCT02290951) showed that in heavily pre-treated patients with B-cell non-Hodgkin …
Displaying drugs 2501 - 2525 of 3304 in total